TXG Stock Cash Flow Statements

10x Genomics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

10x Genomics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31

operating activities:
net income	34,538,000	-34,358,000	-49,028,000	-35,753,000	-37,897,000	-59,949,000	-48,952,000	-92,986,000	-62,414,000	-50,747,000	-17,215,000	-41,914,000	-64,458,000	-42,413,000	-18,449,000	-17,171,000	-11,052,000	-11,551,000	-65,848,000	-40,167,000	-21,143,000	-7,134,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	27,559,000	31,076,000	32,540,000	33,588,000	38,492,000	36,129,000	38,918,000	40,235,000	45,696,000	42,101,000	40,974,000	33,514,000	36,313,000	26,047,000	26,904,000	25,950,000	26,932,000	16,176,000	13,784,000
depreciation and amortization	7,815,000	8,022,000	8,750,000	8,964,000	8,971,000	9,194,000	9,717,000	9,372,000	9,941,000	6,482,000	6,521,000	6,156,000	6,500,000	6,191,000	5,781,000	5,696,000	4,889,000	4,752,000	3,592,000	3,313,000	3,189,000	2,845,000
amortization of right-of-use assets	1,836,000	1,792,000	1,814,000	1,786,000	1,929,000	2,300,000	1,989,000	2,048,000	1,936,000	2,134,000	1,951,000	1,959,000	1,944,000	1,784,000	1,543,000	1,579,000	2,298,000	1,716,000	1,285,000	1,155,000	1,071,000
lease and asset impairment charges	0	114,000	600,000	0	0	2,454,000
realized loss on marketable securities			0	2,000			3,000	0	0	1,715,000
other	-351,000	-575,000	-48,000	62,000	65,000	444,000	-43,000	-143,000	463,000	150,000
changes in operating assets and liabilities:
accounts receivable	2,592,000	35,325,000	-4,370,000	7,683,000	122,000	23,516,000	-10,974,000	-16,165,000	-9,753,000	26,279,000	-20,621,000	-7,352,000	297,000	8,728,000	-6,825,000	-19,392,000	-1,635,000	-6,189,000	-13,300,000	8,125,000	2,521,000	-7,222,000
other receivables
inventory	7,026,000	8,058,000	9,619,000	-4,262,000	-5,197,000	-9,937,000	7,614,000	2,568,000	-1,862,000	-449,000	-1,431,000	-8,660,000	-7,365,000	-3,736,000	-8,783,000	-7,134,000	-5,601,000	-8,614,000	-3,360,000	-2,401,000	-4,087,000	-1,964,000
prepaid expenses and other current assets	4,789,000	-5,530,000	-2,597,000	1,594,000	1,131,000	-2,029,000	1,217,000	-1,523,000	2,130,000	-4,253,000	-2,038,000	2,891,000	-1,475,000	-3,873,000	167,000	-150,000	514,000	-1,584,000	-1,657,000	-2,307,000	601,000	-779,000
other noncurrent assets	125,000	2,314,000	766,000	283,000	-2,349,000	216,000	-388,000	17,783,000	-7,603,000	-10,470,000	514,000	296,000	-42,000	157,000
accounts payable	6,035,000	-2,547,000	-13,398,000	4,339,000	1,122,000	4,583,000	-3,206,000	-4,125,000	2,095,000	-781,000	-224,000	-4,180,000	7,387,000	2,875,000	-1,107,000	2,480,000	-1,174,000	10,885,000	-497,000	-2,157,000	-653,000	2,215,000
accrued compensation and other related benefits	3,928,000	-11,745,000	3,729,000	9,885,000	-580,000	-9,380,000	1,532,000	6,144,000	4,816,000	-15,129,000	4,277,000	4,844,000	5,276,000	-13,283,000	4,469,000	6,138,000	4,428,000	1,302,000	811,000	-8,288,000	6,191,000	4,454,000
deferred revenue	-805,000	347,000	3,067,000	2,310,000	3,712,000	2,120,000	4,295,000	3,752,000	1,834,000	1,051,000	1,505,000	178,000	1,437,000	230,000	314,000	269,000	604,000	348,000	406,000	21,000	471,000	-153,000
accrued expenses and other current liabilities	-7,220,000	4,329,000	4,399,000	-5,008,000	547,000	-12,674,000	19,148,000	8,659,000	655,000	-161,000	469,000	7,789,000	-1,381,000	-3,541,000	1,672,000	3,985,000	702,000	-7,232,000	6,364,000	-1,485,000	4,585,000	3,221,000
operating lease liability	-2,355,000	-2,631,000	-2,721,000	-4,164,000	-2,638,000	-2,961,000	-2,807,000	-1,324,000	-2,232,000	-2,308,000	-1,857,000	-2,385,000	-1,824,000	-357,000	29,000	672,000	-1,746,000	-1,424,000	-1,107,000	-704,000	-1,282,000
other noncurrent liabilities	680,000	360,000	130,000	332,000	65,000	249,000	635,000	401,000	-13,000	261,000	61,000	-3,360,000	151,000	206,000	-620,000	228,000	-775,000	-3,538,000	1,125,000	1,415,000	-5,742,000	367,000
net cash from operating activities	17,708,000	34,351,000	-6,748,000	21,641,000	7,496,000	-15,725,000	25,758,000	-25,304,000	-11,526,000	-4,125,000	13,723,000	-9,564,000	-16,963,000	-20,802,000	5,805,000	-26,216,000	3,120,000	-4,082,000	-55,629,000	-29,518,000	-2,576,000	6,700,000
capex	-1,675,000	-1,495,000	-2,716,000	-4,387,000	-3,325,000	-1,011,000	-3,450,000	-21,653,000	-46,707,000	26,109,000	-39,734,000	-33,961,000	-15,563,000	-13,113,000	-27,618,000	-20,227,000	-14,568,000	-38,865,000	-509,000	-7,096,000	-5,268,000	-8,575,000
free cash flows	16,033,000	32,856,000	-9,464,000	17,254,000	4,171,000	-16,736,000	22,308,000	-46,957,000	-58,233,000	21,984,000	-26,011,000	-43,525,000	-32,526,000	-33,915,000	-21,813,000	-46,443,000	-11,448,000	-42,947,000	-56,138,000	-36,614,000	-7,844,000	-1,875,000
investing activities:
purchases of intangible assets				0
purchases of property and equipment	-1,578,000	-1,893,000	-2,716,000	-3,889,000	-2,878,000	-2,910,000	-3,450,000	-15,236,000	-25,356,000	-4,559,000	-39,734,000	-36,572,000	-27,219,000	-28,136,000	-27,618,000	-20,227,000	-14,568,000	-38,865,000	-509,000	-6,739,000	-8,079,000	-6,556,000
purchases of marketable securities
proceeds from sales of marketable securities			0	271,000	3,017,000	568,000	4,054,000	1,190,000	1,605,000	93,342,000	7,716,000	8,708,000
proceeds from maturities of marketable securities			0	0	12,808,000	12,974,000	12,494,000	19,146,000	19,289,000	31,896,000	1,346,000	8,058,000
net cash from investing activities	-939,000	-1,893,000	-51,592,000	-3,618,000	11,947,000	10,632,000	13,098,000	4,900,000	-4,462,000	119,956,000	-33,172,000	-32,630,000	-27,527,000	-257,558,000	-27,618,000	-20,227,000	-14,568,000	-44,316,000	-1,310,000	-6,739,000	-8,079,000	-6,581,000
financing activities:
issuance of common stock from exercise of stock options and employee stock purchase plan purchases	3,522,000	422,000	4,517,000	156,000			5,613,000	4,374,000			5,001,000	2,039,000			8,903,000	6,683,000	16,193,000	8,546,000	3,921,000
net cash from financing activities	3,522,000	422,000	4,517,000	156,000	4,603,000	1,638,000	5,613,000	4,374,000	7,096,000	-3,414,000	5,001,000	2,039,000	6,360,000	2,417,000	8,903,000	6,683,000	16,193,000	3,518,000	486,968,000	8,051,000	-33,819,000	-1,107,000
effect of exchange rates changes on cash, cash equivalents	360,000	114,000
net increase in cash and cash equivalents	20,651,000	32,994,000		18,335,000	24,043,000	-3,503,000
cash, cash equivalents at beginning of period
cash, cash equivalents at end of period
supplemental disclosures of cash flow information:
cash paid for taxes	856,000	462,000	778,000	2,823,000	1,079,000	961,000	476,000	599,000	1,305,000	2,547,000	276,000	330,000	419,000	2,900,000	342,000	480,000	1,016,000	6,822,000	64,000	43,000	117,000	0
noncash investing and financing activities:
purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	-97,000	398,000		-498,000	-447,000	1,899,000		-6,417,000	-21,351,000	30,668,000		2,611,000	11,656,000	15,023,000						-357,000	2,811,000	-2,019,000
right-of-use assets obtained in exchange for new operating lease liabilities							-652,000	277,000	0	6,893,000		0	0	16,562,000						-76,000	7,634,000
cash, cash equivalents, and restricted cash at beginning of period		344,067,000		0				0	0	227,353,000		0	0	596,073,000		0	0	688,644,000	0	0	476,493,000
cash, cash equivalents, and restricted cash at end of period		377,061,000		18,335,000				-16,115,000	-8,941,000	339,794,000		-40,240,000	-38,322,000	320,112,000		-39,643,000	4,751,000	643,957,000	430,008,000	-28,213,000	431,903,000
purchase of intangible assets									0	-723,000
acquisition of business, net of cash acquired											-2,500,000				0	0	0	-5,451,000
purchase of marketable securities											0	-11,324,000	-29,218,000	-242,329,000
payments on technology license financing arrangement
effect of exchange rate changes on cash, cash equivalents, and restricted cash			-269,000	156,000	-3,000	-48,000	77,000	-85,000	-49,000	24,000	251,000
net increase in cash, cash equivalents, and restricted cash							44,546,000	-16,115,000	-8,941,000	112,441,000					-12,992,000						-44,590,000	-996,000
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
cash paid for interest							0	0	0	436,000	0	0	0	841,000	0	0	0	1,222,000	0	0	1,670,000	528,000
noncash investing and financing activities
purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities
payments on financing arrangement								0	0	-5,814,000		0	0	-5,409,000		0	0	-5,028,000	0	0	-5,846,000
issuance of common stock from exercise of stock options						1,638,000				2,400,000				7,826,000
cash and cash equivalents at beginning of period						359,284,000
cash and cash equivalents at end of period						355,781,000
asset impairment charges
accrued contingent liabilities															0	-29,497,000	-15,352,000	676,000	2,382,000	1,862,000	4,656,000	6,157,000
contingent consideration payable related to business acquisition
lease impairment charges								0
contingent consideration payable from business acquisition												0	0	1,500,000
loss on disposal of property and equipment											631,000	450,000			13,000	0	36,000	30,000				0
loss on extinguishment of debt																			0	0	1,521,000
amortization of premium and accretion of discount on marketable securities											206,000	210,000	272,000	183,000
class a common stock issued for in-process research and development
accretion of discount on term loan																			0	0	17,000	29,000
acquisition of intangible assets
payments on term loans																			0	0	-31,256,000
proceeds from issuance of common stock upon initial and follow-on public offerings, net of issuance costs
net decrease in cash, cash equivalents, and restricted cash												-40,240,000	-38,322,000	-275,961,000			4,751,000	-44,687,000
effect of exchange rates on changes in cash, cash equivalents, and restricted cash													-192,000	-18,000	-82,000	117,000	6,000	193,000	-21,000	-7,000	-116,000	-8,000
proceeds from sales and maturities of marketable securities														12,907,000
deferred rent, noncurrent																						-111,000
proceeds from borrowings under revolver																						0
payments on borrowings under revolver																						0
other assets																131,000	52,000	165,000	392,000	-1,756,000	-1,210,000	-300,000
proceeds from issuance of common stock from follow-on public offering, net of issuance costs
proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs
deferred offering costs
deferred offering costs in accounts payable and accrued expenses and other current liabilities
debt discount in accrued expenses and other current liabilities
stock-based compensation																					6,718,000	5,075,000
proceeds from issuance of common stock upon exercise of stock options																					3,283,000	748,000
proceeds from term loans
payments on capital lease obligations
proceeds from issuance of common stock upon initial public offering, net of issuance costs																						-1,855,000
proceeds from issuance of preferred stock, net of issuance costs
repurchase of unvested common stock related to early exercised shares
conversion of convertible preferred stock into common stock upon initial public offering																						0
purchase of technology licenses under financing arrangement

We provide you with 20 years of cash flow statements for 10x Genomics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of 10x Genomics stock. Explore the full financial landscape of 10x Genomics stock with our expertly curated income statements.

The information provided in this report about 10x Genomics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.